glp-1/gip dual agonist lilly orforglipron oral GLP-1 phase 3 weight loss trial New GLP-1 Guidelines for Type

Moreover, independent blood pressure reduction and plasma lipid modulation further contribute to cardiovascular protection [58,59]

Sampson TR, Challis C, Jain N, et al

While GLP-1R agonists have demonstrated cardiovascular benefits in clinical trials, including reduced rates of major adverse cardiovascular events (MACE) in T2DM patients, their antithrombotic efficacy is generally considered less potent than that of traditional antithrombotic agents

Peptides that influenced multiple physiological pathways were often deemed too complex for therapeutic development, particularly when early studies revealed off-target effects at supraphysiologic doses